Search
Search titles only
By:
Search titles only
By:
Menu
Forums
New posts
Search forums
Home
What's new
New posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Reply to thread
Home
Heath
Alternative Medicine
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
[QUOTE="greenmedinfo, post: 3048"] PMID: J Neurochem. 2021 Sep 13. Epub 2021 Sep 13. PMID: 34519052 Abstract Title: From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. Abstract: The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Much of this interest stems from recent clinical studies demonstrating that they have a unique ability to improve the debilitating symptoms of major depressive disorder (MDD) long-term after only a single treatment. Indeed, the Food and Drug Administration (FDA) has recently designated two Phase III clinical trials studying the ability of psilocybin to treat forms of MDD with "Breakthrough Therapy" status. If successful, the use of psychedelics to treat psychiatric diseases like depression would be revolutionary. As more evidence appears in the scientific literature to support their use in psychiatry to treat MDD on and substance use disorders (SUD), recent studies with rodents revealed that their therapeutic effects might extend beyond treating MDD and SUD. For example, psychedelics may have efficacy in the treatment and prevention of brain injury and neurodegenerative diseases such as Alzheimer's Disease. Preclinical work has highlighted psychedelics' ability to induce neuroplasticity and synaptogenesis, and neural progenitor cell proliferation. Psychedelics may also act as immunomodulators by reducing levels of proinflammatory biomarkers, including IL-1β, IL-6, and tumor necrosis factor-α (TNF-α). Their exact molecular mechanisms, and induction of cellular interactions, especially between neural and glial cells, leading to therapeutic efficacy, remain to be determined. In this review, we discuss recent findings and information on how psychedelics may act therapeutically on cells within the central nervous system (CNS) during brain injuries and neurodegenerative diseases. [URL='https://www.greenmedinfo.com/article/psychiatry-neurology-psychedelics-prospective-therapeutics-neurodegenerative-d']read more[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Home
Heath
Alternative Medicine
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.
Top
Bottom
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…